ProQR to Start Clinical Trial of QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

May 12, 2017: By Jon Swedien

ProQRThe US FDA has given clearance to ProQR Therapeutics’ investigational new drug application for QR-110, a proposed treatment for Leber’s congenital amaurosis Type 10 (LCA 10) patients, the Netherlands company announced April 27.

ProQR said it intends to move forward with a Phase I/II open-label trial to assess the safety, tolerability, pharmacokinetics, and efficacy of multiple administrations of QR-110 in one eye of each patient. ProQR said the trial will include six adults and six children with LCA 10.

Topline results are expected in 2018.

QR-110 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of LCA 10, a mutation in the CEP290 gene. It is intended to be administered through intravitreal injections in the eye. QR-110 has been granted orphan drug designation in the US and European Union, the company said.

LCA 10 leads to progressive loss of vision, causing most patients to lose their sight in the first few years of life. There are no approved treatments or products in clinical development that treat the underlying cause of the disease, ProQR said.

ProQR is focused on RNA medicines for the treatment of severe genetic rare diseases such as LCA 10, cystic fibrosis, and dystrophic epidermolysis bullosa.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022